Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zimmer

This article was originally published in The Gray Sheet

Executive Summary

Bristol-Myers Squibb orthopedics spin-off commences independent public trading Aug. 7 on the New York Stock Exchange under the symbol "ZMH" (1"The Gray Sheet" July 30, 2001, p. 10)

You may also be interested in...



Merit Margin Growth, Cath-Lab Strength Aid Stock's Momentum In August

Merit Medical stock continued to build momentum in August following the July release of strong second quarter financial results that reflect both improving business fundamentals like gross margins and competitive strength in its core cath-lab accessory market.

Merit Margin Growth, Cath-Lab Strength Aid Stock's Momentum In August

Merit Medical stock continued to build momentum in August following the July release of strong second quarter financial results that reflect both improving business fundamentals like gross margins and competitive strength in its core cath-lab accessory market.

Zimmer's NexGen Knees Help Lift Second-Quarter Revenues 13% To $294 Mil.

A 28% jump in U.S. sales of knee implants and a 26% increase in domestic artificial hip revenues helped propel Zimmer Holdings's second-quarter corporate revenues ahead 13% to $294.3 mil., the firm reported July 25.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel